CN109172553A - Tobira glycosides A1 is used to prepare the purposes of the drug for the treatment of human colon carcinoma - Google Patents
Tobira glycosides A1 is used to prepare the purposes of the drug for the treatment of human colon carcinoma Download PDFInfo
- Publication number
- CN109172553A CN109172553A CN201811039559.XA CN201811039559A CN109172553A CN 109172553 A CN109172553 A CN 109172553A CN 201811039559 A CN201811039559 A CN 201811039559A CN 109172553 A CN109172553 A CN 109172553A
- Authority
- CN
- China
- Prior art keywords
- drug
- macrocarpal
- tobira glycosides
- tobira
- glycosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses the purposes that tobira glycosides A1 is used to prepare the drug for the treatment of human colon carcinoma.It is a discovery of the invention that macrocarpal B, tobira glycosides A1 have apparent inhibited proliferation to human colon carcinoma；Macrocarpal C, tobira glycosides A1 have apparent inhibited proliferation to human liver cancer；Macrocarpal B, macrocarpal C, tobira glycosides A1, tobira glycosides A2, without apparent inhibited proliferation, but all have apparent inhibited proliferation to human breast carcinoma to human lung adenocarcinoma.This may be related with the parent nucleus of chemical structure and substituent group type.
Description
Technical field
The invention belongs to biomedicine fields, are related to the discovery of anti-tumor drug.
Background technique
Cancer is also referred to as malignant tumour, is due to the disease that body control cell normal growth mechanism of proliferation is not normal and causes
Disease is one of the disease for seriously threatening human life and health at present.In recent years, China's mortality of malignant tumors, which is in rise, becomes
Gesture, epidemiologic feature analysis the result shows that, 1973~1974 years China's mortality of malignant tumors are 80.79/10 ten thousand people, 1990
~1992 years are 106.76/10 ten thousand people, and 2004~2005 years are 128.63/10 ten thousand people.Currently, the method for oncotherapy is mainly
Drug therapy, operative treatment and radiotherapy.Three great tradition means one of of the chemotherapy as oncotherapy, rise in oncotherapy
Important role, but chemotherapeutics the defects of that there are selective low, toxic side effects is big, multidrug resistance, this is limited significantly
The use of chemotherapeutics.Therefore, the exploitation anti-tumor drug that toxic side effect is small, drug effect is high becomes the hot spot studied at present.
Summary of the invention
The present invention is directed to find the compound with antitumor action, to provide anti-tumor drug.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
Application of the macrocarpal B in the drug of preparation treatment human colon carcinoma.
A kind of pharmaceutical preparation for treating human colon carcinoma, using macrocarpal B as active constituent, also containing can pharmaceutically receive
Carrier, pharmaceutically acceptable dosage form is made.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
Application of the tobira glycosides A1 in the drug of preparation treatment human colon carcinoma.
A kind of pharmaceutical preparation for treating human colon carcinoma, using tobira glycosides A1 as active constituent, also containing can pharmaceutically be connect
Pharmaceutically acceptable dosage form is made in the carrier received.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
Application of the macrocarpal C in the drug of preparation treatment human liver cancer.
A kind of pharmaceutical preparation for treating human liver cancer, using macrocarpal C as active constituent, also containing pharmaceutically acceptable
Pharmaceutically acceptable dosage form is made in carrier.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
Application of the tobira glycosides A1 in the drug of preparation treatment human liver cancer.
A kind of pharmaceutical preparation for treating human liver cancer, using tobira glycosides A1 as active constituent, also containing can pharmaceutically receive
Carrier, pharmaceutically acceptable dosage form is made.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
The application of macrocarpal B or macrocarpal C in the drug of preparation treatment human breast carcinoma.
A kind of pharmaceutical preparation for treating human breast carcinoma also contains medicine using macrocarpal B or macrocarpal C as active constituent
Pharmaceutically acceptable dosage form is made in acceptable carrier on.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
Application of the tobira glycosides A1 or tobira glycosides A2 in the drug of preparation treatment human breast carcinoma.
A kind of pharmaceutical preparation for treating human breast carcinoma also contains using tobira glycosides A1 or tobira glycosides A2 as active constituent
Pharmaceutically acceptable dosage form is made in pharmaceutically acceptable carrier.
Further, the carrier is solid or Auxiliary Liquid Material.
Further, the dosage form includes capsule, tablet, injection.
The utility model has the advantages that
It is a discovery of the invention that macrocarpal B, tobira glycosides A1 have apparent inhibited proliferation to human colon carcinoma；Big fruit
Eucalyptus aldehyde C, tobira glycosides A1 have apparent inhibited proliferation to human liver cancer；Macrocarpal B, macrocarpal C, tobira glycosides
A1, tobira glycosides A2, without apparent inhibited proliferation, but all have apparent proliferation to human breast carcinoma to human lung adenocarcinoma
Inhibiting effect.This may be related with the parent nucleus of chemical structure and substituent group type.
Detailed description of the invention
Fig. 1 is the chemical structural formula of each compound；
Fig. 2 is that each compound composes the inhibition of four kinds of tumours.
Specific embodiment
It is specific with reference to the accompanying drawings and examples to introduce essentiality content of the present invention, but guarantor of the invention is not limited with this
Protect range.
One, experimental material
Macrocarpal B, macrocarpal C, tobira glycosides A1, tobira glycosides A2 purity are not less than 98%, structure such as Fig. 1.
HCT116, HepG2, H1299, MCF-7 tumor cell line are purchased from ATCC.1640, DMEM culture medium, fetal calf serum purchase
From Gibco.MTS cell proliferation reagent is purchased from Amy victory Biovision.
Two, experimental method
1, inhibitory activity of the MTS method measurement target compound to 4 kinds of tumor cell proliferations
Using L029 as positive control drug (it is known to kinds of tumor cells have inhibitory activity, referring to patent
201110456660.7, chemical structural formula such as Fig. 1), reference literature and conventional method carry out experiment.By logarithmic growth phase
HCT116 (human colon carcinoma), HepG2 (human liver cancer), H1299 (human lung adenocarcinoma), MCF-7 (human breast carcinoma) cell, which are used, contains 0.25%
The digestion of the digestive juice of pancreatin and 0.02%EDTA, then with dual anti-(penicillin 100U/ml, streptomysin containing 10%FBS and 1 ‰
Correspondence culture solution 100mg/ml) terminates digestion, and constant volume is made the cell suspension of required concentration (culture solution type and cell are outstanding
Liquid concentration is as shown in table 1).100 μ l of cell suspension is added 96 orifice plates, every piece of 96 orifice plates divide blank group, negative group, solvent group,
Positive drug group and compound group to be sieved (positive drug and compound to be sieved are dissolved with DMSO), every group of 3 multiple holes are empty after cultivating 1d
White group and 100 μ l culture solutions of negative group addition, the culture solution of solvent group addition DMSO containing respective concentration, compound group to be sieved and sun
Property medicine group be separately added into 100 μ l contain compound to be sieved and positive drug culture solution (each group contained substance such as table 2).Continue to cultivate
After 2d, liquid in hole is drawn, 100 μ l culture solutions are added in every hole, after adding 10 μ l MTS, 37 DEG C of culture 2h, in 492nm wavelength
Measure absorbance (A) value.If 6 concentration mensuration IC50 values (100,50,25,12.5,6.25,3.125 μM)
Inhibiting rate (%)=(A solvent-A drug)/(A solvent-A blank) × 100%
Drug includes compound to be sieved (macrocarpal B, macrocarpal C, tobira glycosides A1, tobira glycosides A2) and positive drug
L029.Negative control is used to verify solvent whether cell proliferation has an impact, and uses A solvent to deduct DMSO cell proliferation
It influences.
1 culture solution type of table and concentration of cell suspension
Each group contained substance of table 2
2, data processing
Experimental result data indicates that the comparison among groups of inhibiting rate data use 17.0 software of SPSS with means standard deviation
It carries out one-way analysis of variance and t is examined, P < 0.05 indicates that difference is statistically significant.
Three, experimental result
IC50 value such as 3 and of table that each compound acts on HCT116, HepG2, H1299, MCF-7 Cytostatic to tumor cell
√, which is represented, shown in Fig. 2, in Fig. 2 has apparent inhibited proliferation, × represent without apparent inhibited proliferation.
The IC50 value that each compound of table 3 acts on four kinds of Cytostatic to tumor cell
The above results show that macrocarpal B, tobira glycosides A1 have apparent inhibited proliferation to human colon carcinoma；Greatly
Fruit eucalyptus aldehyde C, tobira glycosides A1 have apparent inhibited proliferation to human liver cancer；Macrocarpal B, macrocarpal C, tobira glycosides
A1, tobira glycosides A2, without apparent inhibited proliferation, but all have apparent proliferation to human breast carcinoma to human lung adenocarcinoma
Inhibiting effect.This may be related with the parent nucleus of chemical structure and substituent group type.
The effect of above-described embodiment is specifically to introduce essentiality content of the invention, but those skilled in the art should know
Protection scope of the present invention should not be confined to the specific embodiment by road.
Claims (4)
1. application of the tobira glycosides A1 in the drug of preparation treatment human colon carcinoma.
2. a kind of pharmaceutical preparation for treating human colon carcinoma, it is characterised in that: using tobira glycosides A1 as active constituent, also contain pharmacy
Upper acceptable carrier, is made pharmaceutically acceptable dosage form.
3. pharmaceutical preparation according to claim 2, it is characterised in that: the carrier is solid or Auxiliary Liquid Material.
4. pharmaceutical preparation according to claim 2, it is characterised in that: the dosage form includes capsule, tablet, injection etc..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811039559.XA CN109172553B (en) | 2018-09-06 | 2018-09-06 | Application of erythrina indica glycoside A1 in preparing medicine for treating human colon cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811039559.XA CN109172553B (en) | 2018-09-06 | 2018-09-06 | Application of erythrina indica glycoside A1 in preparing medicine for treating human colon cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109172553A true CN109172553A (en) | 2019-01-11 |
| CN109172553B CN109172553B (en) | 2020-11-20 |
Family
ID=64915181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811039559.XA Expired - Fee Related CN109172553B (en) | 2018-09-06 | 2018-09-06 | Application of erythrina indica glycoside A1 in preparing medicine for treating human colon cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172553B (en) |
-
2018
- 2018-09-06 CN CN201811039559.XA patent/CN109172553B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN109172553B (en) | 2020-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tataranni et al. | Dichloroacetate (DCA) and cancer: an overview towards clinical applications | |
| CN108358973B (en) | Naphthalimide tetravalent platinum compound, preparation method and application thereof in preparation of antitumor drugs | |
| Yilmaz et al. | Inclusion of quercetin in gold nanoparticles decorated with supramolecular hosts amplifies its tumor targeting properties | |
| Filho et al. | Copper (II) and 2, 2′-bipyridine complexation improves chemopreventive effects of naringenin against breast tumor cells | |
| An et al. | The emerging potential of parthenolide nanoformulations in tumor therapy | |
| CN109091471A (en) | Macrocarpal B is used to prepare the purposes of the drug for the treatment of human colon carcinoma | |
| CN108771663A (en) | The application of macrocarpal B or macrocarpal C in treating breast cancer | |
| CN101402667B (en) | Glycosylation modified nitric oxide donor type oleaolic acid compounds, preparation and uses thereof | |
| CN109172553A (en) | Tobira glycosides A1 is used to prepare the purposes of the drug for the treatment of human colon carcinoma | |
| CN109172554A (en) | Application of the macrocarpal C in terms of the drug of preparation treatment human liver cancer | |
| Ding et al. | Neochamaejasmin A induces mitochondrial‐mediated apoptosis in human hepatoma cells via ROS‐dependent activation of the ERK1/2/JNK signaling pathway | |
| CN108721261A (en) | Applications of the tobira glycosides A1 or tobira glycosides A2 in treating breast cancer | |
| CN108721260A (en) | Applications of the tobira glycosides A1 in terms of the drug for preparing treatment human liver cancer | |
| CN105213366B (en) | The medical usage and its pharmaceutical composition of gamboge ketone compound | |
| CN105399794A (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN111773377B (en) | Application of anidulafungin in preparation of antitumor drugs and antitumor drugs | |
| CN107286123A (en) | A kind of preparation method of dibenzofuran class compound and application | |
| CN106474125A (en) | Peiminine improves the application of the sensitive drug to chemotherapeutics for the tumor cell as preparation | |
| CN110078770B (en) | Compound with quinolinone tetravalent platinum structure, preparation method and application thereof in preparation of antitumor drugs | |
| CN107325148A (en) | A kind of conjugate with antitumor activity and its production and use | |
| KR20220142510A (en) | Use of Astragalus pharmaceutical composition for the manufacture of a drug for enhancing cancer treatment | |
| CN102477039B (en) | Method for preparing Fissistigma oldhamii lactam alkali compound and application thereof to preparing anti-tumour medicine | |
| Devabattula et al. | The potential pharmacological effects of natural product withaferin A in cancer: opportunities and challenges for clinical translation | |
| Kumar et al. | Insight into the Tubulin-Targeted Anticancer Potential of Noscapine and its Structural Analogs | |
| CN103483187A (en) | 4-oxethyl-2-hydroxyl-6-methyl benzoic acid as well as medicinal composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201022 Address after: Room 101, building 132, Baililai scientific innovation town, North Hunan Road, Liaocheng high tech Industrial Development Zone, Shandong Province 252000 Applicant after: Prosense (Shandong) Biomedical Technology Co.,Ltd. Address before: 223001 room 112, Han Hou Avenue, qingJiangpu District, Huaian, Jiangsu, 112 Applicant before: HUAI'AN ANLAI BIOTECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201120 Termination date: 20210906 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |